Transgene S.A. (TRGNF) Stock Price & Analysis
Transgene S.A. (TRGNF) — price $0.80 (0.00%), as of the Nov 19, 2026 trading session; market cap $223M.
Educational signal · not a buy or sell recommendation · How to read this
Transgene S.A. · TRGNF
Transgene SA is a French biotechnology company focused on designing and developing therapeutic vaccines and oncolytic viruses for treating cancers and infectious diseases. Their pipeline includes multiple clinical trials targeting various solid tumors and viral infections, supported by strategic collaborations with major pharmaceutical companies.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.80 | |
| Change on the day | 0.00% | |
| 52-week range | $0.70 – $1.08 | |
| Market capitalisation | $223M | — |
| Shares traded on the day | 1.6K |
Price & events
Other perspectives
Council score for Transgene (TRGNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Transgene (TRGNF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Transgene S.A. (TRGNF) is the company analyzed here. It employs 156 people and is led by Alessandro Riva. In Q2 FY2026 it reported revenue of €269,887 and net income of -€16M. The market values it at $223M.
What do the latest results show for Transgene (TRGNF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €269,887. Against analyst estimates the company has EPS beat 3 of the last 3 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €269,887 | -€16M | -€0.06 (diluted) |
| Q2 FY2025 | €5M | -€19M | -€0.15 (diluted) |
| Q4 FY2024 | €284,000 | -€17M | -€0.18 (diluted) |
What are the financial strengths and risks for Transgene (TRGNF)?
Short answer · as of
The distress and quality screens read Altman Z 2.76 · Piotroski F 3. Trailing ratios: ROE -29.4% · ROA -27.2% · current ratio 9.40 · earnings yield -17.3% · free-cash-flow yield -19.7%.
Data-derived red flags
- Negative return on equity (-29.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TRGNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TRGNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Transgene (TRGNF)?
- Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
- Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
- Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- Transgene to Participate in Investor Access
Transgene Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the TRGNF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is TRGNF a good stock to buy?
Stock Expert AI does not rate TRGNF buy, sell or hold. Transgene S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TRGNF stock price today?
The last price recorded for Transgene S.A. (TRGNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for TRGNF?
The main risks for Transgene SA include the inherent uncertainties associated with clinical trials and regulatory approvals. Failure to achieve positive clinical trial results or secure regulatory approvals for its product candidates could significantly impact the company's prospects.
What are the key factors to evaluate for TRGNF?
Evaluate TRGNF on fundamentals, analyst consensus, and risk factors. Transgene is collaborating with AstraZeneca, Merck KGaA, and Pfizer to advance its research and development programs. Not financial advice.
How frequently does TRGNF data refresh on this page?
TRGNF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TRGNF's recent stock price performance?
Transgene S.A. (TRGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for therapeutic vaccines and oncolytic viruses. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRGNF overvalued or undervalued right now?
Transgene S.A. (TRGNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRGNF before investing?
Before investing in Transgene S.A. (TRGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com